CR

Cancer Research

The Journal of Hepatocellular Carcinoma is an international, peer-reviewed, open access journal that publishes clinical, translational, and basic research on hepatocellular carcinoma, including signaling pathways, molecular tumor classification, therapies, radiology, epidemiology, surveillance, prevention, and quality of life.

Looking to publish in Cancer Research? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Existing customer login
Subject Oncology
Impact Factor 16.6
Quartile Q1
Open Access Type Open
ISSN 0008-5472
eISSN 1538-7445
Invitation Only No
Cost Range Publication involves a base publication fee and an additional fee for each display item; authors may apply for a waiver of the fixed publication fee if no financial support exists.

Submission Instructions

Cancer Research accepts the following article types. Click on an article type to view submission instructions.

Original Research Articles

Cover Letter Cover letter is strongly encouraged for initial submission. Cover letter must describe how any associated manuscript is related to the current submission.
Abstract Abstract is required.
Manuscript Initial submissions do not have strict length restrictions, and the methods section is excluded when calculating manuscript length. Manuscript must be arranged in the following order: title page, text and references, tables, figure legends, and figures. Manuscript must include a conflict of interest disclosure on the title page, a Data Availability subsection at the end of the Materials and Methods or Methods section titled "Data Availability," an Acknowledgments section including funding and any generative AI or other contributors, and a Code Availability Statement if custom computer code was used.
References References must be numbered in order of first mention in the text, cited in the text by number only, and list all authors if there are 6 or fewer or the first 6 authors followed by et al. if there are more than 6.
Figures & Tables For initial submission, figures and tables should be included in a single manuscript file with each figure presented in sequence adjacent to its legend, while supplementary data must be uploaded separately. Each figure must have a legend with a short title sentence and description, multi-panel figures must have labeled panels described in the legend, figure legends must include the number of technical and biological replicates, and tables must have descriptive titles and be numbered with Arabic numerals.
Reformat to Cancer Research using Livewrite Premium

Review Manuscript

Cover Letter Cover letter is strongly encouraged for initial submission.
Abstract Abstract is required.
Manuscript Initial submissions do not have strict length restrictions, and the methods section is excluded when calculating manuscript length. Manuscript must be arranged in the following order: title page, text and references, tables, figure legends, and figures. The manuscript must include a conflict of interest disclosure on the title page, a Data Availability subsection at the end of Materials and Methods, acknowledgments of funding and nonauthor contributors, and declarations of any generative AI use in the acknowledgments or other appropriate section.
References References must be numbered in the order of first mention and cited in the text by number only. List all authors when a reference has 6 or fewer authors, but for more than 6 authors list the first 6 followed by et al.
Figures & Tables For initial submission, figures and tables should be included in a single manuscript file with each figure presented in sequence adjacent to its legend, while supplementary data must be uploaded separately. Each figure must have a legend with a short title and description, multi-panel figures must have labeled panels described in the legend, and figure legends must include the number of technical and biological replicates.
Reformat to Cancer Research using Livewrite Premium

Meta-Analysis

Cover Letter Cover letter is strongly encouraged for initial submission. Cover letter must describe how any associated manuscript is related to the current submission.
Abstract Abstract is required.
Manuscript Initial submissions do not have strict length restrictions, and the methods section is excluded when calculating manuscript length. Manuscript must be arranged in the order of title page, text and references, tables, figure legends, and figures. The manuscript must include a conflict of interest disclosure statement on the title page, a Data Availability subsection at the end of the Materials and Methods or Methods section, an acknowledgment of any generative AI or editing services in the Acknowledgments section, and a declaration of any AI-produced material in an appropriate section of the manuscript.
References References must be numbered in order of first mention in the text, cited by number only, and list all authors if there are 6 or fewer or the first 6 authors followed by et al. if there are more than 6.
Figures & Tables For initial submission, figures and tables should be included in a single manuscript file with each figure presented in sequence adjacent to its legend, while supplementary data must be uploaded separately. Each table must have a descriptive title and Arabic numeral, and each figure must have a legend with a short title sentence and panel descriptions if applicable.
Reformat to Cancer Research using Livewrite Premium

Systematic Reviews

Cover Letter Cover letter is strongly encouraged for initial submission. Cover letter must describe how any associated manuscript is related to the current submission.
Abstract Abstract is required.
Manuscript Initial submissions do not have strict length restrictions, and the methods section is excluded when calculating manuscript length. Manuscript must be arranged in the following order: title page, text and references, tables, figure legends, and figures. Manuscript must include a conflict-of-interest disclosure statement on the title page, a Data Availability subsection at the end of the Materials and Methods, and a declaration of any generative artificial intelligence or human-assisted editing contribution in the acknowledgments or other appropriate section.
References References must be numbered in order of first mention in the text, cited by number only, and list all authors for references with 6 or fewer authors or the first 6 authors followed by et al. for references with more than 6 authors.
Figures & Tables For initial submission, figures and tables should be included in a single manuscript file with each figure presented in sequential order adjacent to its legend, while supplementary data must be uploaded separately. Each table must have a descriptive title and Arabic numeral, and each figure must be cited in order and accompanied by a legend that identifies all panels, symbols, and replicate numbers.
Reformat to Cancer Research using Livewrite Premium

Recent Publications

Targeting Distinct Cell Cycle Nodes Overcomes RAS Inhibitor Resistance

Vishnu Kumarasamy, Jianxin Wang, Edwin H. Yau, Ethan V. Abel, Agnieszka K. Witkiewicz, Erik S. Knudsen

10.1158/0008-5472.can-26-1315
View Publication

EZH2 Inhibition Induces a Metabolic Stress Response Sensitizing Triple-Negative Breast Cancer to Glutaminase Targeting

Lucas Porras, Marina Carrière, Ann-Sophie Gironne, Hugo Philippeau, Gabriel Alzial, Elise Quadri, Jeanne Cormery, Yousef Alaessa, Anie Monast, Faustine Gorse, Myriame St-Arnaud, Mariana De Sa Tavares Russo, Sylvie Nathalie Christine. Mader, Daina Z. Avizonis, Sébastien Lemieux, Morag Park, Geneviève Deblois

10.1158/0008-5472.can-26-0801
View Publication

ScanTCR Enables Early Cancer Detection by Repertoire-Scale Representation of Cancer-Associated T-Cell Receptors in Peripheral Blood

Jinwei Zhang, Yideng Cai, Jinhao Que, Zuxiang Wang, Jing Ma, Yilin Wang, Xiyun Jin, Wenyi Yang, Meng Luo, Zheng Wei, Guangfu Xue, Rongrong Yang, Fenglan Pang, Yi Hui, Wenyang Zhou, Renjie Tan, Pingping Wang, Haoxiu Sun, Zhaochun Xu, Qinghua Jiang

10.1158/0008-5472.can-26-1087
View Publication

Placenta-Related PEG10 Inhibits mRNA Decay to Promote Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma

Xinyi Yao, Bi Wu, Caini Yang, Zhaoyu Lin, Mengting Zhang, Shuang Tao, Jie Chen, Yongxin Huang, Xuyao Chen, Yun Li, Yuntan Qiu, Duanqing Tian, Chengyu Jia, Jingyuan Zhang, Daning Lu, Rui Zhang, Yin Zhang, Dong Yin

10.1158/0008-5472.can-26-0490
View Publication

MYC-Dependent rRNA Catabolism Stress Dictates Survival Heterogeneity of Hepatocellular Carcinoma Cells Under Glutamine Deprivation

Zeyu Yan, Dan Wu, Jingyun Wu, Caiyu Shi, Mengmeng Feng, Yu Li, Gang Wang, Xinwei Liu, Jibin Li, Guoqing Qi, Xianli He, Tingting Ren, Jinliang Xing

10.1158/0008-5472.can-26-0575
View Publication

Frequently asked questions

How long does it take to publish?

Is a cover letter required?

A cover letter is strongly encouraged for initial submission.

Reformat to Cancer Research using Livewrite Premium

What are the publication costs?

Publication involves a base publication fee and an additional fee for each display item. Authors may apply for a waiver of the fixed publication fee if no financial support exists.

Reformat to Cancer Research using Livewrite Premium

Research Topics

Cancer Genomics and Diagnostics Cancer, Hypoxia, and Metabolism RNA modifications and cancer Cancer Research and Treatments Cancer Immunotherapy and Biomarkers Cancer Cells and Metastasis Cancer-related Molecular Pathways Advanced Breast Cancer Therapies Cancer-related molecular mechanisms research Breast Cancer Treatment Studies Epigenetics and DNA Methylation Monoclonal and Polyclonal Antibodies Research Cancer, Lipids, and Metabolism HER2/EGFR in Cancer Research Immunotherapy and Immune Responses Ferroptosis and cancer prognosis Prostate Cancer Treatment and Research CAR-T cell therapy research Cancer Treatment and Pharmacology Lung Cancer Treatments and Mutations Estrogen and related hormone effects Ubiquitin and proteasome pathways Nanoplatforms for cancer theranostics Protein Degradation and Inhibitors Molecular Biology Techniques and Applications

Related Journals

JO
Journal of Clinical Oncology LIPPINCOTT WILLIAMS & WILKINS
CD
Cancer Drug Resistance OAE PUBLISHING INC
JJ
JNCI Journal of the National Cancer Institute Oxford University Press
EJ
European Journal of Surgical Oncology Elsevier BV
JO
Journal of bone oncology Elsevier BV
IJ
International Journal of Clinical Oncology Springer Science+Business Media